학술논문

Potential role of larotrectinib (LOXO-101), a selective pan-TRK inhibitor, in NTRK fusion-positive recurrent glioblastoma
Document Type
Journal
Source
CANCER RESEARCH; JUL 2017, 77 2p. Supplement: 13
Subject
Language
English
ISSN
15387445